Αποτελέσματα Αναζήτησης
25 Φεβ 2015 · New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non-valvular atrial fibrillation (AF). Unlike VKAs, these anticoagulants do not require routine INR monitoring and possess favorable pharmacological properties.
14 Ιουλ 2020 · With the goal of developing a new class of anticoagulants associated with a lower risk of bleeding than currently available agents, dozens of drugs targeting the contact system are now in development.
New oral anticoagulants include direct inhibitors of thrombin, factor Xa and factor IXa. Designed to provide more streamlined anticoagulation than warfarin, these agents can be given without routine coagulation monitoring.
17 Ιουν 2022 · Asundexian showed factor XI inhibition upwards of 90% with daily dosing in PACIFIC-AF. Factor XIa inhibition represents a promising strategy to reduce stroke risk while preserving a patient's ability to clot when bleeding.
15 Νοε 2021 · The development of new anticoagulants usually starts with dose-finding studies involving patients undergoing elective knee arthroplasty, because efficacy can be objectively and...
31 Αυγ 2023 · FXI (factor XI) and FXII (factor XII) have emerged as targets for new anticoagulants that have the potential to be both more efficacious and safer than the currently available direct oral anticoagulants for the prevention and treatment of venous thromboembolism.
19 Μαρ 2015 · The non-vitamin K antagonist oral anticoagulants (NOACs) are replacing warfarin for many indications. These agents include dabigatran, which inhibits thrombin, and rivaroxaban, apixaban, and edoxab...
